# Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

> **NCT03976856** · PHASE1 · UNKNOWN · sponsor: **Genor Biopharma Co., Ltd.** · enrollment: 42 (estimated)

## Conditions studied

- Metastatic Non-small Cell Lung Cancer

## Interventions

- **DRUG:** GB226
- **DRUG:** Fruquintinib

## Key facts

- **NCT ID:** NCT03976856
- **Lead sponsor:** Genor Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-23
- **Primary completion:** 2021-12
- **Final completion:** 2022-12
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2021-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03976856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03976856, "Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03976856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*